Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy

Arunbalaji Pugazhendhi, Margaret Hubbell, Pooja Jairam and 1 more

International Journal of Molecular Sciences · 2021 · Review · CC BY

doi:10.3390/ijms22031170

Abstract

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD’s progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Age-related macular degeneration (AMD) is a degenerative disease of the retina and is the most prevalent retinal disease in the Western world, with the advanced form affecting 1–3% of its total population. AMD accounts for 8.7% of all blindness worldwide and is the most common cause of blindness in developed nations, with the highest prevalence among Europeans compared to African, Hispanic, and Asian populations. The estimated population of those suffering from AMD worldwide is 196 million in 2020, projected to increase to 288 million by 2040 due largely to increasing lifespan globally and Westernization of diet and lifestyle.

AMD is classified into two categories: a neovascular “wet” form and a non-neovascular “dry” form, or a mixture of both, all resulting in partial or complete loss of central vision. While less common than dry AMD, wet or nvAMD accounts for almost 90% of blindness associated with AMD. Dry AMD currently has no treatment, and is characterized by thickening of Bruch’s membrane (BrM) due to lipid and protein accumulation, leading to the formation of sub-retinal pigment epithelium (RPE) deposits called drusen. This deposition interferes with the fluid efflux from the RPE across Bruch’s membrane, chemically and mechanically separating the RPE from the choroid, further reducing perfusion to the RPE. Additional strain is caused by oxidative stress, normal aging, inflammation, and lipofuscin/drusen accumulation, further reducing the flow of nutrients across the Bruch’s membrane. RPE cell death then leads to the loss of photoreceptors, which ultimately leads to loss of vision. In this review, we will discuss etiology and pathophysiology common to AMD as a whole and then focus on those distinct to neovascular AMD plus highlight advances in research and varying treatment modalities for nvAMD to preserve ocular health.

2. Etiology of Neovascular AMD (nvAMD)

nvAMD is a multifactorial disease with numerous risk factors that are thought to play a role in its development. Associated non-modifiable risk factors include increased age, female sex, genetic factors, Caucasian race, and light iris color (Table 1). Modifiable risk factors include smoking, increased BMI, alcohol intake, and dietary habits.

Increasing age is the strongest demographic and leading risk factor associated with AMD, associated with increasing acellular deposits between the RPE and Bruch’s membrane. Patients > 75 years of age had higher 15-year incidences of large drusen, RPE abnormalities, nvAMD, and geographic atrophy (GA) compared to people aged 43 to 54 years, with a 15-year cumulative incidence of late AMD in patients > 75 years at 8%. A pooled meta-analysis of AMD in Europeans (25 studies, n = 57,173) shows a linear increase in the predicted prevalence of AMD, especially in patients > 60 years of age. Progressive failure of repair mechanisms over a lifetime may explain this increased prevalence. One such example is atherosclerosis, the abnormal accumulation of cholesterol plaque within the vascular intima, for which increasing age is the dominant risk factor. Subsequently, atherosclerosis is thought to contribute to AMD by atherosclerotic plaques altering choroidal circulation and venous drainage, therefore increasing blood flow resistance and actively increasing lipid deposition into Bruch’s membrane. In support of this hypothesis, the Rotterdam study reported that atherosclerotic plaques in the carotid bifurcation in subjects below 85 years of age were associated with 4.7 times increased odds of developing and being affected by AMD. In addition, plaques in the common carotid artery as well as lower extremity arterial disease (ankle-arm index less than 0.90 on one side) showed a 2.5× increased prevalence developing AMD. Progression of atherosclerosis is associated with hypertension (which is both modifiable and a disease of senesce), with studies reporting that neovascular AMD was more positively associated with a diastolic blood pressure of >95 mm Hg (Odds ratio (OR) = 4.4).

In addition to age, several studies report that race may also play a significant role in AMD (Table 2), with variations that occur in ethnic and geographic populations. Numerous studies have reported that Caucasians are more likely to develop AMD than blacks, including the Baltimore Eye Study, which reported a four-fold higher risk in whites than in blacks. While Hispanics have been reported to be less susceptible to developing AMD, the overall prevalence of late AMD is 0.5%, and early AMD is increased in the Hispanic population. A meta-analysis of 129,664 individuals among 39 studies reports that the prevalence of early and any AMD in Europeans was 11.2% and 12.3%, respectively, while that in Asians were 6.8% and 7.4%, and 7.1% and 7.5% in Africans, respectively.

Race and associated facial and pigment characteristics may alter the physiological and anatomical configuration, altering the likelihood of certain individuals developing nvAMD. Patients with darker irides have decreased nvAMD incidence, possibly due to increased melanin that absorbs greater light preventing light-induced ROS production and subsequent metabolic demand of the RPE. Caucasians with blue/hazel irides have a greater incidence of extensive macular disease and a greater visual field impairment than dark-colored irides in patients with unilateral nvAMD. The Beaver Dam Eye Study found no correlation among Caucasians compared by hair color, skin sun sensitivity, iris color, and late AMD development at the 10-year follow-up. Pigmentary characteristics on nvAMD incidence is controversial and hypothetical at this moment. In this hypothesis, Asians, who have light-colored skin should have a predisposition to developing nvAMD, however their incidence of nvAMD is reduced compared to Caucasians. This suggests that genetics may also play a vital part in nvAMD progression, with several single-nucleotide polymorphisms seen in nvAMD. The reader is asked to refer to Maguire et al. and DeAngelis et al. for a detailed review on the various genetic loci seen in nvAMD.

While a wide range of studies reveals the impact of intrinsic and genetic influences on nvAMD development, numerous environmental risk factors have been reported (Table 3). Pooled data from the Rotterdam, Beaver Dam Eye, and Blue Mountains studies report a positive correlation with a 2–4-fold likelihood of developing any type of AMD in smokers when compared to non-smokers, suggesting a pathological insult by increased choroidal vascular resistance or oxidative damage to Bruch’s membrane. To determine or measure the insult, a combined analysis of 14,752 participants from the Beaver Dam Eye Study, Rotterdam Study, and Blue Mountains Eye Study discovered that the development of nvAMD is greater (odds ratio 4.55) in smokers compared to non-smokers, with another study showing the time of onset of nvAMD occurs 5.5 years earlier in smokers than in never smokers. It is hypothesized that smoke-induced damage in nvAMD is mediated through direct oxidation, depletion of anti-oxidants, activation of the immune system, as well as atherosclerotic vascular changes. In mouse models, nicotine has been reported to induce pathologic angiogenesis, promoting choroidal neovascularization (CNV). This may be in part due to hypoxia that occurs after smoking, which stimulates the production of vascular endothelial growth factor VEGF, leading to neovascularization. Atherosclerosis or vasoconstriction secondary to smoking may further promote this cycle. Studies exploring the effects of alcohol consumption and AMD development have shown that alcohol increases oxidative damage to the retina. Numerous studies report an increased risk of nvAMD development due to alcohol consumption. According to the 10-year follow up of the Beaver Dam Eye Study, a history of heavy drinking (four or more servings/day, one drink = 12-ounce beer, 4-ounce glass of wine, or 1.5 ounces of liquor) increased the likelihood of developing nvAMD, with a relative risk of 6.51 (adjusted for age and gender), than in non-heavy drinkers (0 servings/day). This suggests a dose-dependent relationship to the development of nvAMD based on the quantity or pattern of alcohol consumption. In contrast, the same researchers found on 15-year follow-up that there was no statistically significant association between heavy drinking and nvAMD development, but reported an increased risk of developing GA in heavy drinkers. Like smoking, increased light exposure, and heavy drinking, body mass index also increases the body’s oxidative stress and is associated with early and late (nvAMD or GA) AMD. For individuals in the obese group (≥30 kg/m2), studies report a 32% increase in the risk of developing late AMD. Additionally, the overweight group individuals (25–29.9 kg/m2) remained insignificant for its association with early and late AMD. The Beaver Dam Eye Study reported increased BMI was associated with early AMD in female non-smokers (hazard ratio (HR) 1.10), and risk of late AMD among female non-smokers with increased with BMI (HR per 2.5 kg/m2 1.31), waist to hip ratio (HR per 0.1 cm/cm 1.95), waist circumference (HR per 5 cm 1.21), and waist to height ratio (HR per 0.1 cm/cm 1.74).

Together with BMI and other lifestyle choices, diet and nutrition are also thought to be modifiable risk factors (Table 3 and Table 4). The Mediterranean/Oriental diet lowers risks of nvAMD, while the Western diet increases the risk of nvAMD. The Mediterranean and Oriental diets are characterized by high consumption of fruits, vegetables, legumes, whole grains, and seafood. These two regional diets have increased intake of micronutrients and lean meats while having reduced processed food in their diet; the Western diet pattern has a higher intake of red meat, processed meat, high-fat dairy products, fried potatoes, refined grains, and eggs. High adherence to the Mediterranean/Oriental diet was associated with a lower risk of advanced and nvAMD, while a high adherence to the Western diet showed an increased incidence for advanced AMD. Higher intake of zinc, vitamin D, α-tocopherol, vitamin C, omega-3 fatty acids, and β-carotene was associated with a reduction of nvAMD by 60–90% with the Mediterranean and Oriental diets containing more nutritionally significant micronutrients than Western diets. Dietary habits may also have a confounding impact on other factors such as body mass index and ethnicity, potentially leading to treatment modalities that target lifestyle modifications.

3. Pathophysiology

nvAMD’s pathophysiology is not fully understood; however, many studies have shown a multifactorial cause among genetic factors, metabolic factors, and environmental factors (Figure 1). Dry AMD is the precursor to wet AMD, with retinal dysfunction causing atrophic changes and subsequently leading to wet AMD. The human retina is composed of roughly 91 million dim, light-sensitive rods, while the number of cones is 4.5 million, all with extremely high metabolic demand. The fovea is populated by a dense array of cones (200× the density in the fovea compared to the rest of the retina). Photoreceptor cells shed ~10% of their volume, and the outer photoreceptor segments (OS) basally regenerate roughly the same volume of cellular material each day, which are phagocytosed by the RPE and metabolically processed into waste products that are then ideally secreted through Bruch’s membrane into the choroidal circulation. Certain byproducts are more taxing to break down, such as lipofuscin. Lipofuscin is a fluorescent material with significant phototoxic potential that is recognized as one of the hallmarks of aging with three defining characteristics: they consist of intracellular secondary lysosomes, they emit yellow fluorescence when excited by near-ultraviolet or blue light, and they accumulate during normal senescence.

Lipofuscin in the retina is formed from the condensation of two molecules of all-trans-retinal and one molecule of phoshatidylethanolamine and is believed to accumulate because of incomplete digestion of the shed OS in the RPE. Once lipofuscin is in the RPE, it is converted to N-Retinylidene-N-Retinylethanolamine (A2E), a pyridinium bis-retinoid, which is toxic to RPE cells. RPE cells cannot dilute A2E by simple cellular division, so there is a progressive buildup of A2E within the cell, which inhibits phagolysosomal degradation of the OS by the RPE. As the hallmark of AMD, drusen are amorphous, extra-cellular debris that accumulate with age in the area between RPE and the inner collagenous zone of Bruch’s membrane. They are categorized into two categories, “hard” and “soft,” depending on their size and shape. Few small hard drusen less than 63 µm can be found in at least 95% of the aged populations, but the presence of larger (≥125 µm) hard drusen, and more importantly, soft drusen (≥125–250 µm) in the macula is considered a major risk factor for developing advanced forms of AMD, including nvAMD.

Drusogenesis is a complex and multifactorial process that takes place over many years. The negative effect of drusen involves drusen formation between RPE and Bruch’s membrane, further decreasing perfusion from the choroid displacing the RPE and photoreceptor layer, effectively distorting vision. Drusen not only acts as a mechanical barrier but also activates the immune system, inducing local inflammation. Drusen is primarily composed of esterified cholesterol (EC), phosphatidylcholine (PC), and protein. Major proteins include vitronectin, complement component 9, apolipoprotein E, clusterin, ATP synthase subunit β, scavenger receptor B2, and retinol dehydrogenase 5. The immune-associated components include dendritic cell processes, major histocompatibility complex (MHC) class II antigens, immunoglobulins, and components of the complement cascade. Recent studies support the hypothesis that deposits between Bruch’s membrane and the RPE may act as a stimulus for the complement system’s local activation. Due to the strong chemotactic activity of complement activation products, there is an influx of inflammatory cells, which may cause further growth of the deposits and subsequent RPE oxidative cell death. The extra-cellular deposits also contribute to local ischemia of RPE cells, which release angiogenic stimuli leading to choroidal neovascularization.

Neovascular AMD, wherein abnormal vessels break through Bruch’s membrane (Figure 2) is one of the leading causes of blindness in the West. It is mediated through several mechanisms. Oxidized low-density lipoproteins, which can exacerbate the deposits in the RPE, inhibit the breakdown of OS in the RPE by delaying the maturation of RPE phagosomes. This leads to the inefficient degradation of the OS and leads to a build-up of undigested lipids and proteins within the RPE, resulting in further production of compounds like A2E. A2E-treated ARPE19 cells increase the expression of pro-angiogenic factors and decreases the expression of anti-angiogenic factors both in vitro and in vivo, with CNV activity greater in A2E-treated eyes. The accumulation of photo-oxidized products in the RPE is believed to be an underlying cause of age-related macular degeneration.

With the retina being one of the highest oxygen-consuming tissues in the body, it is particularly susceptible to oxidative stress because of its high consumption of oxygen, a high proportion of polyunsaturated fatty acids, and its exposure to visible light. The macular pigment acts as a natural barrier protecting the central retina against oxidative damage. The macular pigment (MP) contains three main dietary carotenoids; lutein, zeaxanthin, and meso-zeaxanthin, which forms a natural barrier protecting the retina against oxidative damage, as well as protecting the retina via acting as an optical filter that absorbs short-wave visible light. Reduced intake of carotenoids and smoking is shown to reduce these macular pigments; however, the association with MP reduction and smoking is not yet clear. Still, smoking is a key risk for nvAMD development.

While the MP protects the retina from light oxidation, the shed photoreceptor outer segment membranes are rich in PUFA and can be readily oxidized to induce a cytotoxic chain reaction. The OS segments are degraded in the RPE phagolysosomes, which are not completely digested and aggregate as lipofuscin, deposited in RPE cells’ lysosomes. A2E-loaded RPE cells generated high levels of both hydrogen peroxide (H2O2) and superoxide anion (O2•−) when exposed to blue-violet light, mice deficient in superoxide dismutase develop features of AMD including CNV. Factors like cigarette smoke increase oxidative stress by generating ROS and reducing anti-oxidant capacity. Cigarette smoke has been shown in a mouse model to form sub-RPE deposits, thickening of Bruch’s membrane, and accumulation of deposits within the Bruch’s membrane. Normally, oxidative damage is minimized by the presence of anti-oxidant damage and repair systems, but anti-oxidant systems are affected with smoking, with dietary anti-oxidants such as carotenoids, retinoids, and tocopherols reduced in smokers (after adjusting for dietary intake), but the mechanism behind this reduction is not yet clear. Aging also reduces restorative/ROS coping systems, with increased oxidative damage, including mitochondrial DNA that is more susceptible and essential to the high metabolic demand of RPE. Aging also increases the deposition of beta-amyloid proteins in the eyes. Amyloid proteins are a known constituent of drusen, which can further cause progression to nvAMD.

Another type of cell damage or death is induced by caspases, which are cysteine proteases that initiate cellular programs leading to inflammation or cell death. They can either be pro-inflammatory or proapoptotic, depending on the domain architecture and the described functions. Caspase-1 is produced as an inactive zymogen that is recruited by multi-protein complexes called inflammasomes, which act as molecular platforms activated by cellular stress. They function in the innate immune response for activation of caspase-1, and subsequent secretion of active interleukins (IL-18 and IL- 1β), which mediate the inflammatory response. The NLRP3 inflammasome is a critical component of the innate immune system that is linked with AMD (Figure 3).

IL-18 and IL-1β are synthesized as inactive precursors that require cleavage by caspase-1 to produce biologically active cytokines. IL-1β is considered a classic activator and mediator of inflammation and functions as a potent pro-angiogenic factor by stimulating VEGF production. IL-18 can stimulate both Th1 and Th2 responses depending on the local microenvironment and has been implicated in several inflammatory conditions. IL-18 function has been theorized to have a protective effect in other disease models. IL-18 can play either a protective and/or a pro-inflammatory role, depending on the cell’s immunological status or the type and phase of the inflammatory process.

With drusen and lipofuscin being essential components of nvAMD development, it has been shown that drusen components, as well as A2E, could activate NLRP3 leading to the activation of the caspase-1 cascade. It has been reported that NLRP3 activation can also be caused by oxidative stress and VEGF-A expression. In addition, studies report that a decrease in extra-cellular osmolarity induced a K(+)-dependent conformational change of the preassembled NLRP3-inactive inflammasome during cell swelling, followed by activation of NLRP3, leading to the cascade of caspase activation and resulting inflammatory response to the retina. Chronic inflammation also leads to P2 × 7R activation by ATP released from damaged retinal cells. P2X7R also directly activates the NLRP3 inflammasome causing further inflammation.

NLRP3 was also activated in GA in response to repetitive Alu RNA accumulated in RPE due to a loss of DICER1. Alu RNA was also required for activation of caspase-1 in the inflammasome complex. Alu RNAs are short (approximately 300 base pairs) interspersed nuclear elements transcribed from Alu elements in retrotransposons and are the most abundant repetitive elements in the human genome. DICER1 is an RNase that processes double-stranded and self-complementary RNAs, including a majority of premature micro-RNAs (miRNAs) into their bioactive forms. DICER1 also metabolizes Alu RNAs in humans with DICER1 deficiency implicated in RPE cell death in nvAMD due to accumulation of unprocessed Alu RNAs, resulting in activation of the NLRP3 inflammasome cascade. Wright et al. reported that genetic suppression of DICER1 in three independent mouse models manifested as focal RPE atrophy and aberrant CRNV (choroidal and retinal neovascularization) and that DICER1 expression is reduced in a mouse model of spontaneous CNV. DICER1 as a means of treatment has also been reported, with reports that Aden-associated virus (AAV)-enforced expression of a DICER1 construct successfully escaped miRNA negative feedback, reducing spontaneous CNV in mice. The RPE is crucial to nvAMD development, and a pro-inflammatory retinal environment is promoted by RPE response to various stresses modulating CNV development and progression. The complement system here plays an important role in creating a pro-inflammatory retinal milieu with complement factors C3a and C5a inducing RPE secretion of VEGF and being potent chemotactic agents by recruiting leukocytes to the choroid.

Oxidative stress to the RPE by photo by-products such as lipofuscin activates complement, and the induced autoimmune reaction causes complement deposition in the retina.

There are multiple pathways the RPE can regulate the retinal immune-landscape and, therefore, neovascularization in AMD. In CNV, the macrophage is attracted to the retina with large numbers of retinal macrophages being a hallmark of CNV. However, it could be debated that the increase of macrophages may represent an exacerbation of disease vs. a compensatory vascular-dampening response. In support of macrophages being pro-angiogenic, inhibition of monocyte migration to the retina reduced CNV in a laser-induced mouse model of the disease. In contrast, in a non-injury mouse model of AMD, mice that possess defects in macrophage mobilization develop choroidal neovascularization, suggesting that macrophages somehow also protect against CNV. Given the available evidence, macrophages’ most likely role in CNV is determined by local macrophage-polarizing factors. Undifferentiated M0 macrophages can differentiate into the classical (M1) or alternate (M2) pathway. M1 pathway is pro-inflammatory, and the M2 pathway is anti-inflammatory with stimulation of the M2 macrophages, showing increased angiogenic potential compared to M1 macrophages. The uncertainty of macrophages’ role in CNV is also unclear following anti-vascular treatment, as bevacizumab increases the number of retinal macrophages within human neovascular membranes.Walshe et al. showed that blockage of VEGF-A increased leucocyte-endothelial adhesion (LEA), which could increase retinal macrophage following anti-VEGF treatments, as well as compensatory elevation in VEGF-A levels following anti-VEGF therapy. This warrants further study on the impact and role of retinal macrophages in angiogenesis in AMD.

Another theory of neovascularization is angiopoietin vascular growth factors that activate pathways in the retinal vasculature. Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (Tie2) is a transmembrane receptor that serves as a binding site for hormones angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) ligands. Ang1 is a full endogenous agonist of Tie2 produced in pericytes surrounding the retinal vasculature. Once bound to Tie2, it phosphorylates the receptor, activating downstream pathways that suppress vascular permeability and maintain vascular stability. Conversely, Ang2 is an endogenous weak, partial agonist of Tie2 that competes with Ang1 to suppress phosphorylation and leads to the activation of Tie2. Overexpression of Ang2 and Tie2 antagonism in animal models results in incorrect vessel organization and failure of vessels to mature. Ang1 co-expressed with VEGF-A prevented retinal detachment and blocked neovascularization, while Ang2 is believed to play a role in angiogenesis, vessel destabilization, and inflammation. Elevated Ang2 was also found in the aqueous humor of patients with nvAMD and in the vitreous of diabetic patients undergoing a vitrectomy, further adding proof of its pro-inflammatory and pro-angiogenic nature. Farcizumab is a new anti-VEGF injection that blocks VEGF as well as Ang2, which is currently being tested.

Vascular endothelial growth factor is a potent proangiogenic factor first thought to be an endothelial cell specific mitogen, with physiological functions including bone formation, hematopoiesis, wound healing, and development of the vascular and lymphatic system. VEGF is upregulated in many tumors and is one of the contributing factors of tumor angiogenesis. VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E and placental growth factor (PGF) are members of the VEGF family, with VEGF-A strongly inducing vascular proliferation and migration of endothelial cells essential for both physiological and pathological angiogenesis. The production of VEGF can be induced in hypoxic cells; when cells are in a low-oxygen environment, they produce the transcription of the hypoxia-inducible factor 1 alpha (HIF-1 alpha) inducing the release of VEGF-A. VEGF-A acts via endothelial-specific receptor tyrosine kinases (VEGFR1, VEGFR2) located in endothelial cells, with VEGFR-2 being the most important for angiogenesis. Oxidative stress triggers many other pathways, with the autocrine signaling and upregulation of VEGF being no exception. Oxidative stress and ROS synergize with other pathways (NLRP3, complement cascade, Ang 2, hypoxia), further promoting angiogenesis and progression of nvAMD. Once VEGF-A binds to the receptor, several signaling pathways are activated: (1) the Mitogen-activated protein kinase- (MAPK-) p38 signaling pathway, where the effector heat shock protein (HSP27) reorganizes actin, (2) the phosphatidylinositol 3-kinase- (PI3K-) AKT protein kinase B pathway, promoting the formation of nitric oxide, and (3) the phospholipase C gamma (PLCγ) releasing intracellular calcium, promoting prostaglandin production, increasing vascular permeability. Rearrangement of the cytoskeleton is crucial for various steps of angiogenesis, with actin being a key cytoskeletal element integral for cell division and motility; actin rearrangement leads to formation of protrusive structures, generating intracellular forces required for cell migration. Nitric oxide is a known vasodilator that can lead to upregulation of VEGF by enhancing HIF-1 alpha activity under normoxic conditions.

Under healthy conditions, the production of VEGF upregulates the production of PEDF (pigment epithelium-derived factor) via the RPE. PEDF is a potent endogenous down-regulator of angiogenesis, via intracellular translocation of the transmembrane domain of VEGFR-1. With RPE dysregulation being a key feature of AMD, the protective role of PEDF is reduced, with studies reporting a decrease in PEDF in the choroid of AMD eyes, suggesting that decreased PEDF in the choroid-BrM-RPE creates a non-restrictive environment for the progression to nvAMD.

In nvAMD, anti-VEGF therapy is currently the only treatment available, which only slows down the progression of the disease, however more knowledge about the downstream effects of factors such as VEGF may offer another treatment modality.

4. Treatment

The treatment modalities for nvAMD have greatly evolved over time. The earliest form of nvAMD treatment with laser photocoagulation showed reduced loss of visual acuity (VA) with severe VA loss in 60% of untreated eyes, compared to 25% of eyes treated with argon laser photocoagulation. Krypton red laser photocoagulation for CNV slightly reduced VA loss of six or more lines at three years in 49% of treated eyes vs. 58% of untreated eyes. Photodynamic therapy (PDT) with verteporfin was a predominant treatment for sub-retinal neovascular membrane (SNRVM). When irradiated with a 689 nm laser light, verteporfin releases radical oxygen species that damage the choroidal neovascular endothelium, circumventing the adjacent’s damage retina and resulting in short term cessation of fluorescein leakage from choroidal neovascularization. Through extensive clinical trials (Table 5), anti-VEGF compounds have drastically changed treatment for nvAMD. The first anti-VEGF agent approved for use in nvAMD was Pegaptanib (Macugen). Since then, newer anti-VEGF therapies have emerged and widely replaced the use of Pegaptanib, such as brolucizumab (Beovu), ranibizumab (Lucentis), aflibercept (Eylea), and the off-label use of bevacizumab (Avastin). Anti-VEGF therapy is the mainstay of wet AMD treatment as it affects multiple key pathogenic pathways (Figure 4). Apart from nvAMD, anti-VEGF therapy has been used for other ocular (diabetic macular edema, vascular occlusions, vitreous hemorrhage, severe diabetic retinopathy, neovascular glaucoma, Eales disease, Coats disease, iris neovascularization, post-operative trabeculectomy, pterygium, retinopathy of prematurity, post-operative cystoid macular edema) and oncological diseases (ovarian cancer, gastric cancer, prostate cancer, GIST(Gastrointestinal stromal tumor), pancreatic cancer, non-small cell lung carcinoma).

Ranibizumab (Lucentis) is a 48-kD Fab fragment of the A4.6.1 antibody. The A4.6.1 antibody is one of the four antibodies of the IgG1 isotope that most effectively binds and neutralizes different isomers of VEGF-A. Bevacizumab (Avastin) is a full-length monoclonal antibody (149 kDa) that binds to all isoforms of VEGF-A. It was approved by the FDA in February 2004 for the treatment of metastatic colorectal cancer, and is currently the cheapest of the anti-VEGF drugs. Aflibercept is a 115 kDa fully human, a recombinant fusion protein composed of immunoglobulin binding domain of VEGF receptor 1 and 2, fused to the Fc region of human IgG that binds to VEGF-A, VEGF-B, and placental growth factor (PlGF). In addition to its use as a nonirritating intravitreal injection, it is also used for the treatment of cancer. Aflibercept uniquely binds to PlGF, which is present in human CNV membranes and contributes to the development of experimental CNV. The loss of PIGF signaling seen in aflibercept is also useful in treatment of diabetic retinopathy, as aflibercept leads to blockage of the ERK pathway and subsequent TNF-alpha suppression in high glucose states. Brolucizumab (Beovu) is a humanized single-chain variable fragment (scFv) that is a potent inhibitor of VEGF-A. The scFv comprises the monoclonal antibody’s variable light and heavy chain domains tethered by a flexible linker, resulting in a small fragment weighing approximately 26 kDa, which increases bioavailability, reduces immunogenicity, and allows better ocular tissue penetration. Brolucizumab is the newest anti-VEGF drug on the market, and aims to reduce the number of annual anti-VEGF injections. The HAWK and HARRIER trials compared 3 mg and 6 mg of brolucizumab with 2 mg of aflibercept spaced at 12 weeks (brolucizumab) and 8 weeks (aflibercept), with a reduction to q 8 weeks (brolucizumab) if necessary. In brolucizumab-treated eyes on the q12w regimen at the week 44 in HAWK, there was an 80.5% (3 mg) and 81.5% (6 mg) probability of remaining on an q12w interval until week 92, with a 75.4% for the brolucizumab 6 mg group in HARRIER. The probability of maintaining the q 12-week regimen from loading to week 92 was 39.7% and 45.4% for the brolucizumab 3 mg and 6 mg treatment groups in HAWK, and 38.6% for the 6 mg group in HARRIER. Pluykhova et al. compared the safety profile of long-term use of ranibizumab, bevacizumab, and aflibercepts in the RCT (randomized clinical trial) meta-analysis, with the study hypothesizing the potential benefits of ranibizumab vs. bevacizumab in terms of a systemic safety profile. However, more direct RCT on ocular safety needs to be conducted to validate these findings further.

Future Advancements

Conbercept (143 kDa) is an anti-VEGF agent that consists of the extra-cellular domain 2 of VEGFR1 and extra-cellular domains 3 and 4 of VEGFR2 fused to the Fc portion of human IgG1. Similar to aflibercept, conbercept targets VEGF-A, VEGF-B, and PIGF. Farcizumab is the first bispecific antibody for both VEGF-A and angiopoietin 2 (Ang-2) specifically designed for intraocular use assembled using Roche’s CrossMAb technology, which binds to both VEGF-A and Ang-2 with high affinity and specificity. It has been engineered to abolish certain binding interactions to Fc ϒR and Fc Rn, which increased systemic but not the ocular clearance. Patients treated with farcizumab had a greater mean BCVA increase that was maintained at week 52, with corresponding anatomic improvements compared to ranibizumab.

Ripasudil is a Rho-associated kinase inhibitor developed originally for the treatment of glaucoma and ocular hypertension. Rho-associated protein kinase (ROCK 1 and ROCK 2) determine the macrophage polarization into the M1 and M2 subtypes. Aging increases ROCK2 signaling, resulting in over-expression of the pro-angiogenic macular degeneration associated macrophages, which increases IL-4 leading to angiogenesis. A recent study showed that ripasudil suppressed expression levels of ROCK1, ROCK2, and miR-136-5p, resulting in inhibition of NLRP3, ASC, caspase1, IL-1β, and IL-18.

Gene therapies targeting nvAMD have been performed on animal models, and small-scale clinical trials have been performed on human subjects. Soluble fms-like tyrosine kinase-1(sFlt-1) is an anti-angiogenic receptor for VEGF that binds and causes VEGF sequestration. Animal models of rAAV.sFLT-1 injected mice caused upregulation of sFlt-1, reduced retinal neovascularization. In human studies, small scale r.AAV.sFLT-1 have been conducted with inconclusive results. There are many other vectors/targets being used in gene therapy (Table 6), but gene therapy is currently in its infancy. With the immense potential of gene therapy to treat multiple diseases, more research into the vectors and their targets is needed to further validate possible therapeutic use in nvAMD.

Levodopa’s effects on nvAMD have been studied on the basis that the RPE has a G protein-coupled receptor (GPR143) activated by levodopa. As part of normal aging, melanin, as well as pigment epithelium-derived factor (PEDF), are reduced, and GPR413 activation via signaling reduces VEGF secretion and simultaneously increases PEDF. Studies show that patients using levodopa have a lower risk and a greater age of onset of nvAMD, with Figueroa et al., reporting that levodopa delayed anti-VEGF therapy while improving visual outcomes. In the first month, retinal fluid decreased by 29% without anti-VEGF treatment, with the retinal fluid sustaining for six months. Mean visual acuity improved by 4.7 and 4.8 letters in cohort-1 (levodopa, newly diagnosed, naïve anti-VEGF) and cohort-2 (levodopa, previous anti-VEGF) with a 52% reduction in the need for anti-VEGF injections in Cohort-2.

5. Conclusions

AMD is one of the most common retinal disorders that affect millions, predominantly in the Western world. It is a disease of the developed world with worldwide implications. nvAMD is one subtype that causes 90% of blindness associated with AMD. With the abundant research being conducted, our understanding of nvAMD and the pathologic mechanisms has progressed along with a wide array of treatment modalities, with newer agents being investigated. Anti-VEGF therapy remains the mainstream treatment for slowing the disease’s progression, but is expensive, requires frequent treatments and ultimately does not treat the disease entirely. Due to the success of anti-VEGF therapy, newer anti-VEGF drugs are being research to further increase the treatment efficacy and to reduce cost by prolonging the treatment interval. Due to its multifactorial nature, patients must be educated about modifiable risk factors and the lifestyle changes that can prevent or delay the development of the disease in susceptible individuals. Treatment modalities are evolving that target inflammatory processes, signaling proteins, gene therapies, and newer drugs are currently under trial to treat/delay the disease or prolong the treatment interval.

References 261

  1. 1.

    Wong W.L., Su X., Li X., Cheung C.M., Klein R., Cheng C.Y., Wong T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health. 2014;2:e106-e116.

    Not in our library10.1016/s2214-109x(13)70145-1

  2. 2.

    Chapman N.A., Jacobs R.J., Braakhuis A.J. Role of diet and food intake in age-related macular degeneration: A systematic review. Clin. Exp. Ophthalmol. 2019;47:106-127.

    Not in our library10.1111/ceo.13343

  3. 3.

    Kokotas H., Grigoriadou M., Petersen M.B. Age-related macular degeneration: Genetic and clinical findings. Clin. Chem. Lab. Med. 2011;49:601-616.

    Not in our library10.1515/cclm.2011.091

  4. 4.

    Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001;119:1417-1436.

    Not in our library10.1001/archopht.119.10.1417

  5. 5.

    Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107:2224-2232.

    Not in our library10.1016/s0161-6420(00)00409-7

  6. 6.

    Davis M.D., Gangnon R.E., Lee L.-Y., Hubbard L.D., Klein B.E.K., Klein R., Ferris F.L., Bressler S.B., Milton R.C., Age-Related Eye Disease Study G. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch. Ophthalmol. 2005;123:1484-1498.

    Not in our library10.1001/archopht.123.11.1484

  7. 7.

    Coleman H.R., Chan C.-C., Ferris F.L., Chew E.Y. Age-related macular degeneration. Lancet. 2008;372:1835-1845.

    Not in our library10.1016/s0140-6736(08)61759-6

  8. 8.

    The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: The Age-Related Eye Disease Study Report Number 6. Am. J. Ophthalmol. 2001;132:668-681.

    Not in our library10.1016/s0002-9394(01)01218-1

  9. 9.

    Hyman L., Neborsky R. Risk factors for age-related macular degeneration: An update. Curr. Opin. Ophthalmol. 2002;13:171-175.

    Not in our library10.1097/00055735-200206000-00007

  10. 10.

    Ristau T., Ersoy L., Hahn M., den Hollander A.I., Kirchhof B., Liakopoulos S., Fauser S. Nongenetic Risk Factors for Neovascular Age-Related Macular Degeneration. Investig. Ophthalmol. Vis. Sci. 2014;55:5228-5232.

    Not in our library10.1167/iovs.14-14299

  11. 11.
    Smoking and Age-Related Macular Degeneration: Review and Update · 2013
    No notice
  12. 12.

    Hyman L., Schachat A.P., He Q., Leske M.C. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch. Ophthalmol. 2000;118:351-358.

    Not in our library10.1001/archopht.118.3.351

  13. 13.

    Rudnicka A.R., Jarrar Z., Wormald R., Cook D.G., Fletcher A., Owen C.G. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: A meta-analysis. Ophthalmology. 2012;119:571-580.

    Not in our library10.1016/j.ophtha.2011.09.027

  14. 14.

    Huang J.-D., Presley J.B., Chimento M.F., Curcio C.A., Johnson M. Age-related changes in human macular Bruch’s membrane as seen by quick-freeze/deep-etch. Exp. Eye Res. 2007;85:202-218.

    Not in our library10.1016/j.exer.2007.03.011

  15. 15.

    Buch H., Vinding T., la Cour M., Jensen G.B., Prause J.U., Nielsen N.V. Risk factors for age-related maculopathy in a 14-year follow-up study: The Copenhagen City Eye Study. Acta Ophthalmol. Scand. 2005;83:409-418.

    Not in our library10.1111/j.1600-0420.2005.00492.x

  16. 16.
    The Aging Risk and Atherosclerosis: A Fresh Look at Arterial Homeostasis · 2017
    No notice
  17. 17.

    Kur J., Newman E.A., Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog. Retin. Eye Res. 2012;31:377-406.

    Not in our library10.1016/j.preteyeres.2012.04.004

  18. 18.

    Vingerling J.R., Dielemans I., Bots M.L., Hofman A., Grobbee D.E., de Jong P.T.V.M. Age-related Macular Degeneration Is Associated with Atherosclerosis: The Rotterdam Study. Am. J. Epidemiol. 1995;142:404-409.

    Not in our library10.1093/oxfordjournals.aje.a117648

  19. 19.

    Buford T.W. Hypertension and aging. Ageing Res. Rev. 2016;26:96-111.

    Not in our library10.1016/j.arr.2016.01.007

  20. 20.

    Friedman D.S., Katz J., Bressler N.M., Rahmani B., Tielsch J.M. Racial differences in the prevalence of age-related macular degeneration: The Baltimore eye survey. Ophthalmology. 1999;106:1049-1055.

    Not in our library10.1016/s0161-6420(99)90267-1

  21. 21.

    Bressler S.B., Muñoz B., Solomon S.D., West S.K. The Salisbury Eye Evaluation (SEE) Study Team. Racial Differences in the Prevalence of Age-Related Macular Degeneration: The Salisbury Eye Evaluation (SEE) Project. Arch. Ophthalmol. 2008;126:241-245.

    Not in our library10.1001/archophthalmol.2007.53

  22. 22.

    Clemons T.E., Milton R.C., Klein R., Seddon J.M., Ferris F.L. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112:533-539.

    Not in our library10.1016/j.ophtha.2004.10.047

  23. 23.

    Klein R., Klein B.E., Knudtson M.D., Wong T.Y., Cotch M.F., Liu K., Burke G., Saad M.F., Jacobs D.R. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006;113:373-380.

    Not in our library10.1016/j.ophtha.2005.12.013

  24. 24.

    Muñoz B., Klein R., Rodriguez J., Snyder R., West S.K. Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. Arch. Ophthalmol. 2005;123:1575-1580.

    Not in our library10.1001/archopht.123.11.1575

  25. 25.

    Klein R., Klein B.E., Linton K.L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.

    Not in our library10.1016/s0161-6420(92)31871-8

  26. 26.

    Klein R., Klein B.E., Jensen S.C., Mares-Perlman J.A., Cruickshanks K.J., Palta M. Age-related maculopathy in a multiracial United States population: The National Health and Nutrition Examination Survey III. Ophthalmology. 1999;106:1056-1065.

    Not in our library10.1016/s0161-6420(99)90255-5

  27. 27.

    Varma R., Fraser-Bell S., Tan S., Klein R., Azen S.P. Prevalence of age-related macular degeneration in Latinos: The Los Angeles Latino eye study. Ophthalmology. 2004;111:1288-1297.

    Not in our library10.1016/j.ophtha.2004.01.023

  28. 28.

    Oshima Y., Ishibashi T., Murata T., Tahara Y., Kiyohara Y., Kubota T. Prevalence of age related maculopathy in a representative Japanese population: The Hisayama study. Br. J. Ophthalmol. 2001;85:1153-1157.

    Not in our library10.1136/bjo.85.10.1153

  29. 29.

    Sandberg M.A., Gaudio A.R., Miller S., Weiner A. Iris pigmentation and extent of disease in patients with neovascular age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 1994;35:2734-2740.

    Not in our library

  30. 30.

    Nicolas C.M., Robman L.D., Tikellis G., Dimitrov P.N., Dowrick A., Guymer R.H., McCarty C.A. Iris colour, ethnic origin and progression of age-related macular degeneration. Clin. Exp. Ophthalmol. 2003;31:465-469.

    Not in our library10.1046/j.1442-9071.2003.00711.x

  31. 31.

    Tomany S.C., Klein R., Klein B.E. The relationship between iris color, hair color, and skin sun sensitivity and the 10-year incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 2003;110:1526-1533.

    Not in our library10.1016/s0161-6420(03)00539-6

  32. 32.

    Deangelis M.M., Silveira A.C., Carr E.A., Kim I.K. Genetics of age-related macular degeneration: Current concepts, future directions. Semin. Ophthalmol. 2011;26:77-93.

    Not in our library10.3109/08820538.2011.577129

  33. 33.

    Maguire M.G., Ying G.-S., Jaffe G.J., Toth C.A., Daniel E., Grunwald J., Martin D.F., Hagstrom S.A., Group C.R. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. 2016;134:674-681.

    Not in our library10.1001/jamaophthalmol.2016.0669

  34. 34.

    Mitchell P., Wang J.J., Smith W., Leeder S.R. Smoking and the 5-Year Incidence of Age-Related Maculopathy: The Blue Mountains Eye Study. Arch. Ophthalmol. 2002;120:1357-1363.

    Not in our library10.1001/archopht.120.10.1357

  35. 35.

    Klein R., Klein B.E., Knudtson M.D., Meuer S.M., Swift M., Gangnon R.E. Fifteen-year cumulative incidence of age-related macular degeneration: The Beaver Dam Eye Study. Ophthalmology. 2007;114:253-262.

    Not in our library10.1016/j.ophtha.2006.10.040

  36. 36.

    Klein R., Klein B.E.K., Moss S.E. Relation of Smoking to the Incidence of Age-related Maculopathy: The Beaver Dam Eye Study. Am. J. Epidemiol. 1998;147:103-110.

    Not in our library10.1093/oxfordjournals.aje.a009421

  37. 37.

    Klein R., Klein B.E.K., Tomany S.C., Moss S.E. Ten-Year Incidence of Age-related Maculopathy and Smoking and Drinking: The Beaver Dam Eye Study. Am. J. Epidemiol. 2002;156:589-598.

    Not in our library10.1093/aje/kwf092

  38. 38.

    Thornton J., Edwards R., Mitchell P., Harrison R.A., Buchan I., Kelly S.P. Smoking and age-related macular degeneration: A review of association. Eye. 2005;19:935-944.

    Not in our library10.1038/sj.eye.6701978

  39. 39.

    Hara K. Effects of cigarette smoking on ocular circulation chronic effect on choroidal circulation. Nippon Ganka Gakkai Zasshi. 1991;95:939-943.

    Not in our library

  40. 40.

    Fields M.A., Bowrey H.E., Gong J., Moreira E.F., Cai H., Del Priore L.V. Extracellular matrix nitration alters growth factor release and activates bioactive complement in human retinal pigment epithelial cells. PLoS ONE. 2017;12:e0177763.

    Not in our library10.1371/journal.pone.0177763

  41. 41.
    Chronic Cigarette Smoke Causes Oxidative Damage and Apoptosis to Retinal Pigmented Epithelial Cells in Mice · 2008
    No notice
  42. 42.

    Smith W., Assink J., Klein R., Mitchell P., Klaver C.C.W., Klein B.E.K., Hofman A., Jensen S., Wang J.J., de Jong P.T.V.M. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001;108:697-704.

    Not in our library10.1016/s0161-6420(00)00580-7

  43. 43.

    Khan J.C., Thurlby D.A., Shahid H., Clayton D.G., Yates J.R.W., Bradley M., Moore A.T., Bird A.C. Smoking and age related macular degeneration: The number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br. J. Ophthalmol. 2006;90:75.

    Not in our library10.1136/bjo.2005.073643

  44. 44.

    Suner I.J., Espinosa–Heidmann D.G., Pereira–Simon S., Piña Y., Cousins S.W. Cigarette Smoke Increases Severity of Experimental Choroidal Neovascularization (CNV): Role of Inflammation. Investig. Ophthalmol. Vis. Sci. 2005;46:3507.

    Not in our library

  45. 45.

    Lee J., Cooke J.P. Nicotine and pathological angiogenesis. Life Sci. 2012;91:1058-1064.

    Not in our library10.1016/j.lfs.2012.06.032

  46. 46.

    Chang M.A., Bressler S.B., Munoz B., West S.K. Racial Differences and Other Risk Factors for Incidence and Progression of Age-Related Macular Degeneration: Salisbury Eye Evaluation (SEE) Project. Investig. Ophthalmol. Vis. Sci. 2008;49:2395-2402.

    Not in our library10.1167/iovs.07-1584

  47. 47.

    Akishima S., Matsushita S., Sato F., Hyodo K., Imazuru T., Enomoto Y., Noma M., Hiramatsu Y., Shigeta O., Sakakibara Y. Cigarette-smoke-induced vasoconstriction of peripheral arteries: Evaluation by synchrotron radiation microangiography. Circ. J. 2007;71:418-422.

    Not in our library10.1253/circj.71.418

  48. 48.

    Cederbaum A.I. Role of lipid peroxidation and oxidative stress in alcohol toxicity. Free Radic. Biol. Med. 1989;7:537-539.

    Not in our library10.1016/0891-5849(89)90029-4

  49. 49.

    Chong E.W., Kreis A.J., Wong T.Y., Simpson J.A., Guymer R.H. Alcohol consumption and the risk of age-related macular degeneration: A systematic review and meta-analysis. Am. J. Ophthalmol. 2008;145:707-715.

    Not in our library10.1016/j.ajo.2007.12.005

  50. 50.

    Arnarsson A., Sverrisson T., Stefánsson E., Sigurdsson H., Sasaki H., Sasaki K., Jonasson F. Risk Factors for Five-Year Incident Age-related Macular Degeneration: The Reykjavik Eye Study. Am. J. Ophthalmol. 2006;142:419-428.e411.

    Not in our library10.1016/j.ajo.2006.04.015

  51. 51.

    Coleman A.L., Seitzman R.L., Cummings S.R., Yu F., Cauley J.A., Ensrud K.E., Stone K.L., Hochberg M.C., Pedula K.L., Thomas E.L., et al. The Association of Smoking and Alcohol Use With Age-related Macular Degeneration in the Oldest Old: The Study of Osteoporotic Fractures. Am. J. Ophthalmol. 2010;149:160-169.

    Not in our library10.1016/j.ajo.2009.07.025

  52. 52.

    Knudtson M.D., Klein R., Klein B.E.K. Alcohol consumption and the 15-year cumulative incidence of age-related macular degeneration. Am. J. Ophthalmol. 2007;143:1026-1029.

    Not in our library10.1016/j.ajo.2007.01.036

  53. 53.

    Adams M.K.M., Chong E.W., Williamson E., Aung K.Z., Makeyeva G.A., Giles G.G., English D.R., Hopper J., Guymer R.H., Baird P.N., et al. 20/20—Alcohol and Age-related Macular Degeneration: The Melbourne Collaborative Cohort Study. Am. J. Epidemiol. 2012;176:289-298.

    Not in our library10.1093/aje/kws004

  54. 54.

    Manna P., Jain S.K. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. Metab. Syndr. Relat. Disord. 2015;13:423-444.

    Not in our library10.1089/met.2015.0095

  55. 55.

    Zhang Q.Y., Tie L.J., Wu S.S., Lv P.L., Huang H.W., Wang W.Q., Wang H., Ma L. Overweight, Obesity, and Risk of Age-Related Macular Degeneration. Investig. Ophthalmol. Vis. Sci. 2016;57:1276-1283.

    Not in our library10.1167/iovs.15-18637

  56. 56.

    Howard K.P., Klein B.E.K., Lee K.E., Klein R. Measures of body shape and adiposity as related to incidence of age-related eye diseases: Observations from the Beaver Dam Eye Study. Investig. Ophthalmol. Vis. Sci. 2014;55:2592-2598.

    Not in our library10.1167/iovs.13-13763

  57. 57.

    Vingerling J.R., Hofman A., Grobbee D.E., de Jong P.T.V.M. Age-Related Macular Degeneration and Smoking: The Rotterdam Study. Arch. Ophthalmol. 1996;114:1193-1196.

    Not in our library10.1001/archopht.1996.01100140393005

  58. 58.

    Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology. 2002;180:121-137.

    Not in our library10.1016/s0300-483x(02)00386-4

  59. 59.

    Rohrer B., Frazer-Abel A., Leonard A., Ratnapriya R., Ward T., Pietraszkiewicz A., O’Quinn E., Adams K., Swaroop A., Wolf B.J. Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent. Mol. Vis. 2019;25:79-92.

    Not in our library

  60. 60.

    Lee J., Cooke J.P. The role of nicotine in the pathogenesis of atherosclerosis. Atherosclerosis. 2011;215:281-283.

    Not in our library10.1016/j.atherosclerosis.2011.01.003

  61. 61.

    Tsukamoto H., Lu S.C. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J. 2001;15:1335-1349.

    Not in our library10.1096/fj.00-0650rev

  62. 62.
    Oxidative Stress in Obesity: A Critical Component in Human Diseases · 2014
    No notice
  63. 63.

    Dai J., Jones D.P., Goldberg J., Ziegler T.R., Bostick R.M., Wilson P.W., Manatunga A.K., Shallenberger L., Jones L., Vaccarino V. Association between adherence to the Mediterranean diet and oxidative stress. Am. J. Clin. Nutr. 2008;88:1364-1370.

    Not in our library10.3945/ajcn.2008.26528

  64. 64.

    Cougnard-Grégoire A., Merle B.M., Korobelnik J.F., Rougier M.B., Delyfer M.N., Le Goff M., Samieri C., Dartigues J.F., Delcourt C. Olive Oil Consumption and Age-Related Macular Degeneration: The Alienor Study. PLoS ONE. 2016;11:e0160240.

    Not in our library10.1371/journal.pone.0160240

  65. 65.

    Merle B.M.J., Silver R.E., Rosner B., Seddon J.M. Adherence to a Mediterranean diet, genetic susceptibility, and progression to advanced macular degeneration: A prospective cohort study. Am. J. Clin. Nutr. 2015;102:1196-1206.

    Not in our library10.3945/ajcn.115.111047

  66. 66.

    Chiu C.-J., Chang M.-L., Zhang F.F., Li T., Gensler G., Schleicher M., Taylor A. The relationship of major American dietary patterns to age-related macular degeneration. Am. J. Ophthalmol. 2014;158:118-127.e111.

    Not in our library10.1016/j.ajo.2014.04.016

  67. 67.

    Romagnolo D.F., Selmin O.I. Mediterranean Diet and Prevention of Chronic Diseases. Nutr. Today. 2017;52:208-222.

    Not in our library10.1097/nt.0000000000000228

  68. 68.
    The Mediterranean Diet and Nutritional Adequacy: A Review · 2014
    No notice
  69. 69.

    Serra-Majem L., Bes-Rastrollo M., Román-Viñas B., Pfrimer K., Sánchez-Villegas A., Martínez-González M.A. Dietary patterns and nutritional adequacy in a Mediterranean country. Br. J. Nutr. 2009;101:S21-S28.

    Not in our library10.1017/s0007114509990559

  70. 70.
    National, regional, and global trends in adult overweight and obesity prevalences · 2012
    No notice
  71. 71.

    Gunes F.E., Bekiroglu N., Imeryuz N., Agirbasli M. Relation between eating habits and a high body mass index among freshman students: A cross-sectional study. J. Am. Coll. Nutr. 2012;31:167-174.

    Not in our library10.1080/07315724.2012.10720024

  72. 72.

    Aoki A., Inoue M., Nguyen E., Obata R., Kadonosono K., Shinkai S., Hashimoto H., Sasaki S., Yanagi Y. Dietary n-3 Fatty Acid, α-Tocopherol, Zinc, vitamin D, vitamin C and β-carotene are Associated with Age-Related Macular Degeneration in Japan. Sci. Rep. 2016;6:20723.

    Not in our library10.1038/srep20723

  73. 73.

    Hogg R.E., Woodside J.V., McGrath A., Young I.S., Vioque J.L., Chakravarthy U., de Jong P.T., Rahu M., Seland J., Soubrane G., et al. Mediterranean Diet Score and Its Association with Age-Related Macular Degeneration: The European Eye Study. Ophthalmology. 2017;124:82-89.

    Not in our library10.1016/j.ophtha.2016.09.019

  74. 74.

    SanGiovanni J.P., Chew E.Y., Clemons T.E., Davis M.D., Ferris F.L., Gensler G.R., Kurinij N., Lindblad A.S., Milton R.C., Seddon J.M., et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch. Ophthalmol. 2007;125:671-679.

    Not in our library10.1001/archopht.125.5.671

  75. 75.

    Okubo A., Rosa R.H., Bunce C.V., Alexander R.A., Fan J.T., Bird A.C., Luthert P.J. The relationships of age changes in retinal pigment epithelium and Bruch’s membrane. Investig. Ophthalmol. Vis. Sci. 1999;40:443-449.

    Not in our library

  76. 76.

    Al-Zamil W.M., Yassin S.A. Recent developments in age-related macular degeneration: A review. Clin. Interv. Aging. 2017;12:1313-1330.

    Not in our library10.2147/cia.s143508

  77. 77.
    Age‐Related Macular Degeneration: New Paradigms for Treatment and Management of AMD · 2018
    No notice
  78. 78.

    Purves D., Augustine G.J., Fitzpatrick D., Katz L.C., LaMantia A.-S., McNamara J.-O., Williams M. Anatomical Distribution of Rods and Cones. Neuroscience. 2001.

    Not in our library

  79. 79.

    Kevany B.M., Palczewski K. Phagocytosis of retinal rod and cone photoreceptors. Physiology (Bethesda). 2010;25:8-15.

    Not in our library10.1152/physiol.00038.2009

  80. 80.

    Brunk U.T., Terman A. Lipofuscin: Mechanisms of age-related accumulation and influence on cell. Free Radic. Biol. Med. 2002;33:611-619.

    Not in our library10.1016/s0891-5849(02)00959-0

  81. 81.

    Katz M.L., Robison W.G. What is lipofuscin? Defining characteristics and differentiation from other autofluorescent lysosomal storage bodies. Arch. Gerontol. Geriatr. 2002;34:169-184.

    Not in our library10.1016/s0167-4943(02)00005-5

  82. 82.

    Sparrow J.R., Wu Y., Kim C.Y., Zhou J. Phospholipid meets all-trans-retinal: The making of RPE bisretinoids. J. Lipid. Res. 2010;51:247-261.

    Not in our library10.1194/jlr.r000687

  83. 83.

    Kennedy C.J., Rakoczy P.E., Constable I.J. Lipofuscin of the retinal pigment epithelium: A review. Eye (Lond). 1995;9:763-771.

    Not in our library10.1038/eye.1995.192

  84. 84.

    Finnemann S., Leung L., Rodriguez-Boulan E. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. Proc. Natl. Acad. Sci. USA. 2002;99:3842-3847.

    Not in our library10.1073/pnas.052025899

  85. 85.

    Nowak J.Z. Age-related macular degeneration (AMD): Pathogenesis and therapy. Pharm. Rep. 2006;58:353-363.

    Not in our library

  86. 86.
    Abundant Lipid and Protein Components of Drusen · 2010
    No notice
  87. 87.

    Ambati J., Atkinson J.P., Gelfand B.D. Immunology of age-related macular degeneration. Nat. Rev. Immunol. 2013;13:438-451.

    Not in our library10.1038/nri3459

  88. 88.

    Jorgenson E., Melles R.B., Hoffmann T.J., Jia X., Sakoda L.C., Kvale M.N., Banda Y., Schaefer C., Risch N., Shen L. Common coding variants in the HLA-DQB1 region confer susceptibility to age-related macular degeneration. Eur. J. Hum. Genet. 2016;24:1049-1055.

    Not in our library10.1038/ejhg.2015.247

  89. 89.

    Nita M., Strzałka-Mrozik B., Grzybowski A., Mazurek U., Romaniuk W. Age-related macular degeneration and changes in the extracellular matrix. Med. Sci. Monit. 2014;20:1003-1016.

    Not in our library10.12659/msm.889887

  90. 90.

    Mullins R.F., Russell S.R., Anderson D.H., Hageman G.S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835-846.

    Not in our library10.1096/fasebj.14.7.835

  91. 91.

    Kijlstra A., La Heij E., Hendrikse F. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul. Immunol. Inflamm. 2005;13:3-11.

    Not in our library10.1080/09273940590909185

  92. 92.

    Hoppe G., O’Neil J., Hoff H.F., Sears J. Accumulation of oxidized lipid-protein complexes alters phagosome maturation in retinal pigment epithelium. Cell. Mol. Life. Sci. 2004;61:1664-1674.

    Not in our library10.1007/s00018-004-4080-5

  93. 93.

    Iriyama A., Yanagi Y., Inoue Y., Takahashi H., Tamaki Y. Role of A2E in the Pathogenesis of CNV. Investig. Ophthalmol. Vis. Sci. 2006;47:4146.

    Not in our library

  94. 94.

    Beatty S., Koh H., Phil M., Henson D., Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000;45:115-134.

    Not in our library10.1016/s0039-6257(00)00140-5

  95. 95.

    Loskutova E., Nolan J., Howard A., Beatty S. Macular pigment and its contribution to vision. Nutrients. 2013;5:1962-1969.

    Not in our library10.3390/nu5061962

  96. 96.

    Drobek-Słowik M., Karczewicz D., Safranow K. The potential role of oxidative stress in the pathogenesis of the age-related macular degeneration (AMD). Postepy Hig. Med. Dosw. (Online). 2007;61:28-37.

    Not in our library

  97. 97.

    Wiktorowska-Owczarek A., Nowak J.Z. Pathogenesis and prophylaxis of AMD: Focus on oxidative stress and antioxidants. Postepy Hig. Med. Dosw. (Online). 2010;64:333-343.

    Not in our library

  98. 98.

    Hammond B.R., Wooten B.R., Snodderly D.M. Cigarette smoking and retinal carotenoids: Implications for age-related macular degeneration. Vis. Res. 1996;36:3003-3009.

    Not in our library10.1016/0042-6989(96)00008-9

  99. 99.

    Wu J., Cho E., Willett W.C., Sastry S.M., Schaumberg D.A. Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up. JAMA Ophthalmol. 2015;133:1415-1424.

    Not in our library10.1001/jamaophthalmol.2015.3590

  100. 100.
    Light action spectrum on oxidative stress and mitochondrial damage in A2E-loaded retinal pigment epithelium cells · 2018
    No notice
  101. 101.

    Dong A., Xie B., Shen J., Yoshida T., Yokoi K., Hackett S.F., Campochiaro P.A. Oxidative stress promotes ocular neovascularization. J. Cell Physiol. 2009;219:544-552.

    Not in our library10.1002/jcp.21698

  102. 102.

    Davies K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life. 2000;50:279-289.

    Not in our library10.1080/15216540051081010

  103. 103.

    Espinosa-Heidmann D.G., Suner I.J., Catanuto P., Hernandez E.P., Marin-Castano M.E., Cousins S.W. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Investig. Ophthalmol. Vis. Sci. 2006;47:729-737.

    Not in our library10.1167/iovs.05-0719

  104. 104.

    Gabriel H.E., Liu Z., Crott J.W., Choi S.-W., Song B.C., Mason J.B., Johnson E.J. A Comparison of Carotenoids, Retinoids, and Tocopherols in the Serum and Buccal Mucosa of Chronic Cigarette Smokers versus Nonsmokers. Cancer Epidemiol. Biomark. Amplif. Amplif. Prev. 2006;15:993.

    Not in our library10.1158/1055-9965.epi-05-0664

  105. 105.

    Rimm E., Colditz G. Smoking, Alcohol, and Plasma Levels of Carotenes and Vitamin Ea. Ann. N. Y. Acad. Sci. 1993;686:323-333.

    Not in our library10.1111/j.1749-6632.1993.tb39195.x

  106. 106.

    Shokolenko I., Venediktova N., Bochkareva A., Wilson G.L., Alexeyev M.F. Oxidative stress induces degradation of mitochondrial DNA. Nucleic. Acids Res. 2009;37:2539-2548.

    Not in our library10.1093/nar/gkp100

  107. 107.
    Viewing ageing eyes: diverse sites of amyloid Beta accumulation in the ageing mouse retina and the up-regulation of macrophages. · 2010
    Not checked
  108. 108.

    Fisichella V., Giurdanella G., Platania C.B., Romano G.L., Leggio G.M., Salomone S., Drago F., Caraci F., Bucolo C. TGF-β1 prevents rat retinal insult induced by amyloid-β (1-42) oligomers. Eur. J. Pharm. 2016;787:72-77.

    Not in our library10.1016/j.ejphar.2016.02.002

  109. 109.

    Julien O., Wells J.A. Caspases and their substrates. Cell Death Differ. 2017;24:1380-1389.

    Not in our library10.1038/cdd.2017.44

  110. 110.

    Van Opdenbosch N., Lamkanfi M. Caspases in Cell Death, Inflammation, and Disease. Immunity. 2019;50:1352-1364.

    Not in our library10.1016/j.immuni.2019.05.020

  111. 111.
    The Inflammasomes · 2009
    No notice
  112. 112.

    Martinon F., Burns K., Tschopp J. The Inflammasome: A Molecular Platform Triggering Activation of Inflammatory Caspases and Processing of proIL-β. Mol. Cell. 2002;10:417-426.

    Not in our library10.1016/s1097-2765(02)00599-3

  113. 113.

    Kosmidou C., Efstathiou N.E., Hoang M.V., Notomi S., Konstantinou E.K., Hirano M., Takahashi K., Maidana D.E., Tsoka P., Young L., et al. Issues with the Specificity of Immunological Reagents for NLRP3: Implications for Age-related Macular Degeneration. Sci. Rep. 2018;8:461.

    Not in our library10.1038/s41598-017-17634-1

  114. 114.

    Dinarello C.A. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr. 2006;83:447s-455s.

    Not in our library10.1093/ajcn/83.2.447s

  115. 115.
    The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation · 2019
    No notice
  116. 116.

    Jha S., Ting J.P.Y. Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases. J. Immunol. 2009;183:7623-7629.

    Not in our library10.4049/jimmunol.0902425

  117. 117.
    The role IL-1 in tumor-mediated angiogenesis · 2014
    No notice
  118. 118.

    Krishnan S.M., Sobey C.G., Latz E., Mansell A., Drummond G.R. IL-1β and IL-18: Inflammatory markers or mediators of hypertension? Br. J. Pharm. 2014;171:5589-5602.

    Not in our library10.1111/bph.12876

  119. 119.
    IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis · 2019
    No notice
  120. 120.

    Kim E.J., Cho D., Kim T.S. Efficient induction of T helper type 1-mediated immune responses in antigen-primed mice by anti-CD3 single-chain Fv/interleukin-18 fusion DNA. Immunology. 2004;111:27-34.

    Not in our library10.1111/j.1365-2567.2004.01784.x

  121. 121.

    Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 2001;19:423-474.

    Not in our library10.1146/annurev.immunol.19.1.423

  122. 122.

    Doyle S.L., Campbell M., Ozaki E., Salomon R.G., Mori A., Kenna P.F., Farrar G.J., Kiang A.-S., Humphries M.M., Lavelle E.C., et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat. Med. 2012;18:791-798.

    Not in our library10.1038/nm.2717

  123. 123.

    Bamias G., Corridoni D., Pizarro T.T., Cominelli F. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine. 2012;59:451-459.

    Not in our library10.1016/j.cyto.2012.06.014

  124. 124.

    Anderson O.A., Finkelstein A., Shima D.T. A2E induces IL-1ß production in retinal pigment epithelial cells via the NLRP3 inflammasome. PLoS ONE. 2013;8:e67263.

    Not in our library10.1371/journal.pone.0067263

  125. 125.

    Liu R.T., Gao J., Cao S., Sandhu N., Cui J.Z., Chou C.L., Fang E., Matsubara J.A. Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: Implications for inflammasome activation in age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2013;54:2225-2237.

    Not in our library10.1167/iovs.12-10849

  126. 126.

    Shimada K., Crother T.R., Karlin J., Dagvadorj J., Chiba N., Chen S., Ramanujan V.K., Wolf A.J., Vergnes L., Ojcius D.M., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401-414.

    Not in our library10.1016/j.immuni.2012.01.009

  127. 127.

    Kauppinen A., Niskanen H., Suuronen T., Kinnunen K., Salminen A., Kaarniranta K. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells--implications for age-related macular degeneration (AMD). Immunol. Lett. 2012;147:29-33.

    Not in our library10.1016/j.imlet.2012.05.005

  128. 128.

    Marneros A.G. NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration. Cell Rep. 2013;4:945-958.

    Not in our library10.1016/j.celrep.2013.08.002

  129. 129.

    Compan V., Baroja-Mazo A., López-Castejón G., Gomez A.I., Martínez C.M., Angosto D., Montero M.T., Herranz A.S., Bazán E., Reimers D., et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity. 2012;37:487-500.

    Not in our library10.1016/j.immuni.2012.06.013

  130. 130.

    Platania C.B.M., Giurdanella G., Di Paola L., Leggio G.M., Drago F., Salomone S., Bucolo C. P2X7 receptor antagonism: Implications in diabetic retinopathy. Biochem. Pharm. 2017;138:130-139.

    Not in our library10.1016/j.bcp.2017.05.001

  131. 131.

    Kim Y., Tarallo V., Kerur N., Yasuma T., Gelfand B.D., Bastos-Carvalho A., Hirano Y., Yasuma R., Mizutani T., Fowler B.J., et al. DICER1/Alu RNA dysmetabolism induces Caspase-8–mediated cell death in age-related macular degeneration. Proc. Natl. Acad. Sci. USA. 2014;111:16082.

    Not in our library10.1073/pnas.1403814111

  132. 132.

    Tarallo V., Hirano Y., Gelfand B.D., Dridi S., Kerur N., Kim Y., Cho W.G., Kaneko H., Fowler B.J., Bogdanovich S., et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell. 2012;149:847-859.

    Not in our library10.1016/j.cell.2012.03.036

  133. 133.

    Häsler J., Strub K. Alu elements as regulators of gene expression. Nucleic. Acids Res. 2006;34:5491-5497.

    Not in our library10.1093/nar/gkl706

  134. 134.

    Bernstein E., Caudy A.A., Hammond S.M., Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363-366.

    Not in our library10.1038/35053110

  135. 135.

    Du Z., Lee J.K., Tjhen R., Stroud R.M., James T.L. Structural and biochemical insights into the dicing mechanism of mouse Dicer: A conserved lysine is critical for dsRNA cleavage. Proc. Natl. Acad. Sci. USA. 2008;105:2391-2396.

    Not in our library10.1073/pnas.0711506105

  136. 136.

    Kaneko H., Dridi S., Tarallo V., Gelfand B., Fowler B., Cho W., Kleinman M., Ponicsan S., Hauswirth W., Chiodo V., et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 2011;471:325-330.

    Not in our library10.1038/nature09830

  137. 137.

    Wright C.B., Uehara H., Kim Y., Yasuma T., Yasuma R., Hirahara S., Makin R.D., Apicella I., Pereira F., Nagasaka Y., et al. Chronic Dicer1 deficiency promotes atrophic and neovascular outer retinal pathologies in mice. Proc. Natl. Acad. Sci. USA. 2020;117:2579-2587.

    Not in our library10.1073/pnas.1909761117

  138. 138.

    Nozaki M., Raisler B.J., Sakurai E., Sarma J.V., Barnum S.R., Lambris J.D., Chen Y., Zhang K., Ambati B.K., Baffi J.Z., et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA. 2006;103:2328-2333.

    Not in our library10.1073/pnas.0408835103

  139. 139.

    Zhou J., Jang Y.P., Kim S.R., Sparrow J.R. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc. Natl. Acad. Sci. USA. 2006;103:16182-16187.

    Not in our library10.1073/pnas.0604255103

  140. 140.

    Ambati J., Fowler B.J. Mechanisms of age-related macular degeneration. Neuron. 2012;75:26-39.

    Not in our library10.1016/j.neuron.2012.06.018

  141. 141.

    Espinosa-Heidmann D.G., Suner I.J., Hernandez E.P., Monroy D., Csaky K.G., Cousins S.W. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Investig. Ophthalmol. Vis. Sci. 2003;44:3586-3592.

    Not in our library10.1167/iovs.03-0038

  142. 142.

    Sakurai E., Anand A., Ambati B.K., van Rooijen N., Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Investig. Ophthalmol. Vis. Sci. 2003;44:3578-3585.

    Not in our library10.1167/iovs.03-0097

  143. 143.

    Ambati J., Anand A., Fernandez S., Sakurai E., Lynn B.C., Kuziel W.A., Rollins B.J., Ambati B.K. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 2003;9:1390-1397.

    Not in our library10.1038/nm950

  144. 144.

    Tsutsui H., Yoshimoto T., Hayashi N., Mizutani H., Nakanishi K. Induction of allergic inflammation by interleukin-18 in experimental animal models. Immunol. Rev. 2004;202:115-138.

    Not in our library10.1111/j.0105-2896.2004.00205.x

  145. 145.

    Sica A., Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Investig. 2012;122:787-795.

    Not in our library10.1172/jci59643

  146. 146.
    ROCK-Isoform-Specific Polarization of Macrophages Associated with Age-Related Macular Degeneration · 2015
    Not checked
  147. 147.

    Jetten N., Verbruggen S., Gijbels M.J., Post M.J., De Winther M.P., Donners M.M. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis. 2014;17:109-118.

    Not in our library10.1007/s10456-013-9381-6

  148. 148.

    Tatar O., Yoeruek E., Szurman P., Bartz-Schmidt K.U., Adam A., Shinoda K., Eckardt C., Boeyden V., Claes C., Pertile G., et al. Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization. Arch. Ophthalmol. 2008;126:782-790.

    Not in our library10.1001/archopht.126.6.782

  149. 149.

    Walshe T.E., Dole V.S., Maharaj A.S.R., Patten I.S., Wagner D.D., D’Amore P.A. Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arter. Thromb. Vasc. Biol. 2009;29:1185-1192.

    Not in our library10.1161/atvbaha.109.186742

  150. 150.

    Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004;10:145-147.

    Not in our library10.1038/nm988

  151. 151.

    Leppänen V.-M., Saharinen P., Alitalo K. Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. Proc. Natl. Acad. Sci. USA. 2017;114:4376.

    Not in our library10.1073/pnas.1616166114

  152. 152.

    Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161-1169.

    Not in our library10.1016/s0092-8674(00)81812-7

  153. 153.

    Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.

    Not in our library10.1126/science.277.5322.55

  154. 154.

    Nambu H., Umeda N., Kachi S., Oshima Y., Akiyama H., Nambu R., Campochiaro P.A. Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J. Cell Physiol. 2005;204:227-235.

    Not in our library10.1002/jcp.20292

  155. 155.

    Fiedler U., Reiss Y., Scharpfenecker M., Grunow V., Koidl S., Thurston G., Gale N.W., Witzenrath M., Rosseau S., Suttorp N., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat. Med. 2006;12:235-239.

    Not in our library10.1038/nm1351

  156. 156.

    Thurston G., Daly C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb. Perspect. Med. 2012;2:a006550.

    Not in our library10.1101/cshperspect.a006650

  157. 157.

    Ng D.S., Yip Y.W., Bakthavatsalam M., Chen L.J., Ng T.K., Lai T.Y., Pang C.P., Brelén M.E. Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Sci. Rep. 2017;7:45081.

    Not in our library10.1038/srep45081

  158. 158.

    Watanabe D., Suzuma K., Suzuma I., Ohashi H., Ojima T., Kurimoto M., Murakami T., Kimura T., Takagi H. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 2005;139:476-481.

    Not in our library10.1016/j.ajo.2004.10.004

  159. 159.

    Sahni J., Patel S.S., Dugel P.U., Khanani A.M., Jhaveri C.D., Wykoff C.C., Hershberger V.S., Pauly-Evers M., Sadikhov S., Szczesny P., et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019;126:1155-1170.

    Not in our library10.1016/j.ophtha.2019.03.023

  160. 160.

    Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989;161:851-858.

    Not in our library10.1016/0006-291x(89)92678-8

  161. 161.

    Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 1999;5:623-628.

    Not in our library10.1038/9467

  162. 162.

    Gerber H.P., Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. (Berl.). 2003;81:20-31.

    Not in our library10.1007/s00109-002-0397-4

  163. 163.

    Johnson K.E., Wilgus T.A. Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair. Adv. Wound Care (New Rochelle). 2014;3:647-661.

    Not in our library10.1089/wound.2013.0517

  164. 164.

    Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298.

    Not in our library10.1002/j.1460-2075.1996.tb00359.x

  165. 165.

    Coultas L., Chawengsaksophak K., Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438:937-945.

    Not in our library10.1038/nature04479

  166. 166.

    Verheul H.M., Pinedo H.M. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin. Breast Cancer. 2000;1(Suppl. 1):S80-S84.

    Not in our library10.3816/cbc.2000.s.015

  167. 167.

    Li X., Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int. J. Biochem. Cell Biol. 2001;33:421-426.

    Not in our library10.1016/s1357-2725(01)00027-9

  168. 168.

    Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.

    Not in our library10.1126/science.2479986

  169. 169.

    Oommen S., Gupta S.K., Vlahakis N.E. Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: Identification of a specific {alpha}9{beta}1 binding site. J. Biol. Chem. 2011;286:1083-1092.

    Not in our library10.1074/jbc.m110.175158

  170. 170.

    Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996;16:4604-4613.

    Not in our library10.1128/mcb.16.9.4604

  171. 171.

    Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009;21:154-165.

    Not in our library10.1016/j.ceb.2008.12.012

  172. 172.

    Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.

    Not in our library10.1096/fasebj.13.1.9

  173. 173.

    Monaghan-Benson E., Hartmann J., Vendrov A.E., Budd S., Byfield G., Parker A., Ahmad F., Huang W., Runge M., Burridge K., et al. The role of vascular endothelial growth factor-induced activation of NADPH oxidase in choroidal endothelial cells and choroidal neovascularization. Am. J. Pathol. 2010;177:2091-2102.

    Not in our library10.2353/ajpath.2010.090878

  174. 174.

    Rossino M.G., Lulli M., Amato R., Cammalleri M., Monte M.D., Casini G. Oxidative Stress Induces a VEGF Autocrine Loop in the Retina: Relevance for Diabetic Retinopathy. Cells. 2020;9:1452.

    Not in our library10.3390/cells9061452

  175. 175.

    Rousseau S., Houle F., Landry J., Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169-2177.

    Not in our library10.1038/sj.onc.1201380

  176. 176.

    Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.-O., Buerk D.G., Huang P.L., Jain R.K. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA. 2001;98:2604-2609.

    Not in our library10.1073/pnas.041359198

  177. 177.

    Feliers D., Chen X., Akis N., Choudhury G.G., Madaio M., Kasinath B.S. VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int. 2005;68:1648-1659.

    Not in our library10.1111/j.1523-1755.2005.00575.x

  178. 178.

    McLaughlin A.P., De Vries G.W. Role of PLCgamma and Ca(2+) in VEGF- and FGF-induced choroidal endothelial cell proliferation. Am. J. Physiol. Cell Physiol. 2001;281:C1448-C1456.

    Not in our library10.1152/ajpcell.2001.281.5.c1448

  179. 179.

    Murohara T., Horowitz J.R., Silver M., Tsurumi Y., Chen D., Sullivan A., Isner J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998;97:99-107.

    Not in our library10.1161/01.cir.97.1.99

  180. 180.

    Bayless K.J., Johnson G.A. Role of the cytoskeleton in formation and maintenance of angiogenic sprouts. J. Vasc. Res. 2011;48:369-385.

    Not in our library10.1159/000324751

  181. 181.

    Pollard T.D., Borisy G.G. Cellular Motility Driven by Assembly and Disassembly of Actin Filaments. Cell. 2003;112:453-465.

    Not in our library10.1016/s0092-8674(03)00120-x

  182. 182.

    Zhou Q., Anderson C., Zhang H., Li X., Inglis F., Jayagopal A., Wang S. Repression of Choroidal Neovascularization Through Actin Cytoskeleton Pathways by MicroRNA-24. Mol. Ther. 2014;22:378-389.

    Not in our library10.1038/mt.2013.243

  183. 183.

    Dulak J., Józkowicz A., Dembinska-Kiec A., Guevara I., Zdzienicka A., Zmudzinska-Grochot D., Florek I., Wójtowicz A., Szuba A., Cooke J.P. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arter. Thromb. Vasc. Biol. 2000;20:659-666.

    Not in our library10.1161/01.atv.20.3.659

  184. 184.

    Kuwabara M., Kakinuma Y., Ando M., Katare R.G., Yamasaki F., Doi Y., Sato T. Nitric oxide stimulates vascular endothelial growth factor production in cardiomyocytes involved in angiogenesis. J. Physiol. Sci. 2006;56:95-101.

    Not in our library10.2170/physiolsci.rp002305

  185. 185.

    Ohno-Matsui K., Morita I., Tombran-Tink J., Mrazek D., Onodera M., Uetama T., Hayano M., Murota S.I., Mochizuki M. Novel mechanism for age-related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF. J. Cell Physiol. 2001;189:323-333.

    Not in our library10.1002/jcp.10026

  186. 186.

    Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D’Amore P.A., Folkman J. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 1993;193:631-638.

    Not in our library10.1006/bbrc.1993.1671

  187. 187.

    Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., Bouck N.P. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science. 1999;285:245-248.

    Not in our library10.1126/science.285.5425.245

  188. 188.

    Cai J., Jiang W.G., Grant M.B., Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J. Biol. Chem. 2006;281:3604-3613.

    Not in our library10.1074/jbc.m507401200

  189. 189.

    Mitter S.K., Song C., Qi X., Mao H., Rao H., Akin D., Lewin A., Grant M., Dunn W., Ding J., et al. Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. Autophagy. 2014;10:1989-2005.

    Not in our library10.4161/auto.36184

  190. 190.

    Holekamp N.M., Bouck N., Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. 2002;134:220-227.

    Not in our library10.1016/s0002-9394(02)01549-0

  191. 191.

    Duh E.J., Yang H.S., Suzuma I., Miyagi M., Youngman E., Mori K., Katai M., Yan L., Suzuma K., West K., et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Investig. Ophthalmol. Vis. Sci. 2002;43:821-829.

    Not in our library

  192. 192.

    Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol. 1982;100:912-918.

    Not in our library10.1001/archopht.1982.01030030920003

  193. 193.

    Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch. Ophthalmol. 1990;108:816-824.

    Not in our library10.1001/archopht.1990.01070080058036

  194. 194.

    Schlötzer-Schrehardt U., Viestenz A., Naumann G.O., Laqua H., Michels S., Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefe‘s Arch. Clin. Exp. Ophthalmol. 2002;240:748-757.

    Not in our library10.1007/s00417-002-0517-4

  195. 195.

    Donati G., Kapetanios A.D., Pournaras C.J. Principles of treatment of choroidal neovascularization with photodynamic therapy in age-related macular degeneration. Semin. Ophthalmol. 1999;14:2-10.

    Not in our library10.3109/08820539909056057

  196. 196.

    Miller J.W., Schmidt-Erfurth U., Sickenberg M., Pournaras C.J., Laqua H., Barbazetto I., Zografos L., Piguet B., Donati G., Lane A.M., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a phase 1 and 2 study. Arch. Ophthalmol. 1999;117:1161-1173.

    Not in our library10.1001/archopht.117.9.1161

  197. 197.

    Schmidt-Erfurth U., Miller J.W., Sickenberg M., Laqua H., Barbazetto I., Gragoudas E.S., Zografos L., Piguet B., Pournaras C.J., Donati G., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of retreatments in a phase 1 and 2 study. Arch. Ophthalmol. 1999;117:1177-1187.

    Not in our library10.1001/archopht.117.9.1177

  198. 198.

    Chakravarthy U., Adamis A.P., Cunningham E.T., Goldbaum M., Guyer D.R., Katz B., Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508.e1-25.

    Not in our library10.1016/j.ophtha.2006.02.064

  199. 199.

    Clearkin L., Ramasamy B., Wason J., Tiew S. Anti-VEGF intervention in neovascular AMD: Benefits and risks restated as natural frequencies. BMJ Open Ophthalmol. 2019;4:e000257.

    Not in our library10.1136/bmjophth-2018-000257

  200. 200.

    Stefanini F.R., Badaró E., Falabella P., Koss M., Farah M.E., Maia M. Anti-VEGF for the management of diabetic macular edema. J. Immunol. Res. 2014;2014:632307.

    Not in our library10.1155/2014/632307

  201. 201.

    Campa C., Alivernini G., Bolletta E., Parodi M.B., Perri P. Anti-VEGF Therapy for Retinal Vein Occlusions. Curr. Drug Targets. 2016;17:328-336.

    Not in our library10.2174/1573399811666150615151324

  202. 202.

    El Annan J., Carvounis P.E. Current management of vitreous hemorrhage due to proliferative diabetic retinopathy. Int. Ophthalmol. Clin. 2014;54:141-153.

    Not in our library10.1097/iio.0000000000000027

  203. 203.

    Zhao Y., Singh R.P. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context. 2018;7:212532.

    Not in our library10.7573/dic.212532

  204. 204.

    Simha A., Aziz K., Braganza A., Abraham L., Samuel P., Lindsley K.B. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst. Rev. 2020;2:Cd007920.

    Not in our library10.1002/14651858.cd007920.pub3

  205. 205.

    Cp J., Al G., Jd L. Combination of intravitreal bevacizumab and peripheral photocoagulation: An alternative treatment in eales disease. Med. Hypothesis Discov. Innov. Ophthalmol. 2013;2:30-34.

    Not in our library

  206. 206.

    Li S., Deng G., Liu J., Ma Y., Lu H. The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease. BMC Ophthalmol. 2017;17:76.

    Not in our library10.1186/s12886-017-0469-4

  207. 207.

    Xia T., Zarbin M.A., Bhagat N. Anti-VEGF for Management of Neovascularization of Iris and Neovascular Glaucoma. J. Vitreoretinal Dis. 2018;2:194-199.

    Not in our library10.1177/2474126418782067

  208. 208.

    Slabaugh M., Salim S. Use of Anti-VEGF Agents in Glaucoma Surgery. J. Ophthalmol. 2017;2017:1645269.

    Not in our library10.1155/2017/1645269

  209. 209.

    Mak R.K., Chan T.C., Marcet M.M., Choy B.N., Shum J.W., Shih K.C., Wong I.Y., Ng A.L. Use of anti-vascular endothelial growth factor in the management of pterygium. Acta Ophthalmol. 2017;95:20-27.

    Not in our library10.1111/aos.13178

  210. 210.

    Tran K.D., Cernichiaro-Espinosa L.A., Berrocal A.M. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy. Asia Pac. J. Ophthalmol. (Phila). 2018;7:56-62.

    Not in our library10.22608/apo.2017436

  211. 211.

    Ghasemi Falavarjani K., Parvaresh M.-M., Modarres M., Hashemi M., Samiy N. Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review. J. Ophthalmic. Vis. Res. 2012;7:235-239.

    Not in our library

  212. 212.

    Monk B.J., Minion L.E., Coleman R.L. Anti-angiogenic agents in ovarian cancer: Past, present, and future. Ann. Oncol. 2016;27(Suppl. 1):i33-i39.

    Not in our library10.1093/annonc/mdw093

  213. 213.

    Park D.J., Thomas N.J., Yoon C., Yoon S.S. Vascular endothelial growth factor a inhibition in gastric cancer. Gastric. Cancer. 2015;18:33-42.

    Not in our library10.1007/s10120-014-0397-4

  214. 214.
    Targeting Angiogenesis in Prostate Cancer · 2019
    No notice
  215. 215.

    Blanke C.D., Rankin C., Corless C., Eary J.F., Mulder K., Okuno S.H., George S., Heinrich M. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist. 2015;20:1353-1354.

    Not in our library10.1634/theoncologist.2015-0295

  216. 216.

    Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.L., Verslype C., Scheithauer W., Shang A., Cosaert J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 2009;27:2231-2237.

    Not in our library10.1200/jco.2008.20.0238

  217. 217.

    Korpanty G., Smyth E., Carney D.N. Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? J. Thorac. Dis. 2011;3:19-29.

    Not in our library10.3978/j.issn.2072-1439.2010.11.11

  218. 218.

    Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355:1419-1431.

    Not in our library10.1056/nejmoa054481

  219. 219.

    Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., Schneider S. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. N. Engl. J. Med. 2006;355:1432-1444.

    Not in our library10.1056/nejmoa062655

  220. 220.

    Ho A.C., Busbee B.G., Regillo C.D., Wieland M.R., Van Everen S.A., Li Z., Rubio R.G., Lai P. Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Ophthalmology. 2014;121:2181-2192.

    Not in our library10.1016/j.ophtha.2014.05.009

  221. 221.

    Wykoff C.C., Croft D.E., Brown D.M., Wang R., Payne J.F., Clark L., Abdelfattah N.S., Sadda S.R. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015;122:2514-2522.

    Not in our library10.1016/j.ophtha.2015.08.009

  222. 222.

    Antoszyk A.N., Tuomi L., Chung C.Y., Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results. Am. J. Ophthalmol. 2008;145:862-874.

    Not in our library10.1016/j.ajo.2007.12.029

  223. 223.

    Schauwvlieghe A.M., Dijkman G., Hooymans J.M., Verbraak F.D., Hoyng C.B., Dijkgraaf M.G., Peto T., Vingerling J.R., Schlingemann R.O. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS ONE. 2016;11:e0153052.

    Not in our library10.1371/journal.pone.0153052

  224. 224.

    Berg K., Pedersen T.R., Sandvik L., Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122:146-152.

    Not in our library10.1016/j.ophtha.2014.07.041

  225. 225.

    Martin D.F., Maguire M.G., Fine S.L., Ying G.S., Jaffe G.J., Grunwald J.E., Toth C., Redford M., Ferris F.L. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology. 2012;119:1388-1398.

    Not in our library10.1016/j.ophtha.2012.03.053

  226. 226.

    Kodjikian L., Souied E.H., Mimoun G., Mauget-Faÿsse M., Behar-Cohen F., Decullier E., Huot L., Aulagner G. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013;120:2300-2309.

    Not in our library10.1016/j.ophtha.2013.06.020

  227. 227.

    Chakravarthy U., Harding S.P., Rogers C.A., Downes S.M., Lotery A.J., Culliford L.A., Reeves B.C. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258-1267.

    Not in our library10.1016/s0140-6736(13)61501-9

  228. 228.

    Heier J.S., Brown D.M., Chong V., Korobelnik J.F., Kaiser P.K., Nguyen Q.D., Kirchhof B., Ho A., Ogura Y., Yancopoulos G.D., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548.

    Not in our library10.1016/j.ophtha.2012.09.006

  229. 229.

    Dugel P.U., Koh A., Ogura Y., Jaffe G.J., Schmidt-Erfurth U., Brown D.M., Gomes A.V., Warburton J., Weichselberger A., Holz F.G. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:72-84.

    Not in our library10.1016/j.ophtha.2019.04.017

  230. 230.

    Li X., Xu G., Wang Y., Xu X., Liu X., Tang S., Zhang F., Zhang J., Tang L., Wu Q., et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: Results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121:1740-1747.

    Not in our library10.1016/j.ophtha.2014.03.026

  231. 231.

    Liu K., Song Y., Xu G., Ye J., Wu Z., Liu X., Dong X., Zhang M., Xing Y., Zhu S., et al. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. Am. J. Ophthalmol. 2019;197:156-167.

    Not in our library10.1016/j.ajo.2018.08.026

  232. 232.

    Danzig C., Quezada C., Basu K., Grzeschik S., Sahni J., Silverman D., Osborne A. Efficacy and safety of faricimab every 16 or 12 weeks for neovascular age-related macular degeneration: STAIRWAY phase 2 results. Investig. Ophthalmol. Vis. Sci. 2019;60:1212.

    Not in our library

  233. 233.

    Lien S., Lowman H.B. Therapeutic anti-VEGF antibodies. Handb. Exp. Pharm. 2008;131-150.

    Not in our library10.1007/978-3-540-73259-4_6

  234. 234.

    Blick S.K., Keating G.M., Wagstaff A.J. Ranibizumab. Drugs. 2007;67:1199-1206.

    Not in our library10.2165/00003495-200767080-00007

  235. 235.

    Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004;3:391-400.

    Not in our library10.1038/nrd1381

  236. 236.

    van Asten F., Michels C.T.J., Hoyng C.B., van der Wilt G.J., Klevering B.J., Rovers M.M., Grutters J.P.C. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. PLoS ONE. 2018;13:e0197670.

    Not in our library10.1371/journal.pone.0197670

  237. 237.

    Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001;7:575-583.

    Not in our library10.1038/87904

  238. 238.

    Stewart M.W., Grippon S., Kirkpatrick P. Aflibercept. Nat. Rev. Drug Discov. 2012;11:269-270.

    Not in our library10.1038/nrd3700

  239. 239.

    Lazzara F., Fidilio A., Platania C.B.M., Giurdanella G., Salomone S., Leggio G.M., Tarallo V., Cicatiello V., De Falco S., Eandi C.M., et al. Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway. Biochem. Pharm. 2019;168:341-351.

    Not in our library10.1016/j.bcp.2019.07.021

  240. 240.

    Fernandes C.F.C., Pereira S.D.S., Luiz M.B., Zuliani J.P., Furtado G.P., Stabeli R.G. Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases. Front. Immunol. 2017;8:653.

    Not in our library10.3389/fimmu.2017.00653

  241. 241.

    Gaudreault J., Gunde T., Floyd H.S., Ellis J., Tietz J., Binggeli D., Keller B., Schmidt A., Escher D. Preclinical Pharmacology and Safety of ESBA1008, a Single-chain Antibody Fragment, Investigated as Potential Treatment for Age Related Macular Degeneration. Investig. Ophthalmol. Vis. Sci. 2012;53:3025.

    Not in our library

  242. 242.

    Plyukhova A.A., Budzinskaya M.V., Starostin K.M., Rejdak R., Bucolo C., Reibaldi M., Toro M.D. Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. J. Clin. Med. 2020;9:1522.

    Not in our library10.3390/jcm9051522

  243. 243.

    Zhang M., Yu D., Yang C., Xia Q., Li W., Liu B., Li H. The Pharmacology Study of a New Recombinant Human VEGF Receptor-Fc Fusion Protein on Experimental Choroidal Neovascularization. Pharm. Res. 2009;26:204-210.

    Not in our library10.1007/s11095-008-9718-9

  244. 244.

    Zhang X., Wu J., Wu C., Bian A.-l., Geng S., Dai R.-p. Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection. Diabetes Res. Clin. Pract. 2020;162:108083.

    Not in our library10.1016/j.diabres.2020.108083

  245. 245.
    Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases · 2016
    Corrected
  246. 246.

    Garnock-Jones K.P. Ripasudil: First global approval. Drugs. 2014;74:2211-2215.

    Not in our library10.1007/s40265-014-0333-2

  247. 247.

    Gao Z., Li Q., Zhang Y., Gao X., Li H., Yuan Z. Ripasudil alleviated the inflammation of RPE cells by targeting the miR-136-5p/ROCK/NLRP3 pathway. BMC Ophthalmol. 2020;20:134.

    Not in our library10.1186/s12886-020-01400-5

  248. 248.

    Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., Albuquerque R.J., Richter E., Sakurai E., Newcomb M.T., et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-997.

    Not in our library10.1038/nature05249

  249. 249.

    Lai C.-M., Estcourt M.J., Wikstrom M., Himbeck R.P., Barnett N.L., Brankov M., Tee L.B.G., Dunlop S.A., Degli-Esposti M.A., Rakoczy E.P. rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector. Investig. Ophthalmol. Vis. Sci. 2009;50:4279-4287.

    Not in our library10.1167/iovs.08-3253

  250. 250.

    Rakoczy E.P., Magno A.L., Lai C.M., Pierce C.M., Degli-Esposti M.A., Blumenkranz M.S., Constable I.J. Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration. Am. J. Ophthalmol. 2019;204:113-123.

    Not in our library10.1016/j.ajo.2019.03.006

  251. 251.

    Constable I.J., Pierce C.M., Lai C.-M., Magno A.L., Degli-Esposti M.A., French M.A., McAllister I.L., Butler S., Barone S.B., Schwartz S.D., et al. Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration. EBioMedicine. 2016;14:168-175.

    Not in our library10.1016/j.ebiom.2016.11.016

  252. 252.

    EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005.

    Not in our library

  253. 253.

    RGX-314 Gene Therapy for Neovascular AMD Trial.

    Not in our library

  254. 254.

    Safety and Tolerability Study of AAV2-sFLT01 in Patients with Neovascular Age-Related Macular Degeneration (AMD).

    Not in our library

  255. 255.

    Study of AdGVPEDF.11D in Neovascular Age-Related Macular Degeneration (AMD).

    Not in our library

  256. 256.

    A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients with Age-Related Macular Degeneration.

    Not in our library

  257. 257.

    Safety and Efficacy Study of rAAV.sFlt-1 in Patients with Exudative Age-Related Macular Degeneration.

    Not in our library

  258. 258.

    AAVCAGsCD59 for the Treatment of Wet AMD.

    Not in our library

  259. 259.

    ADVM-022 Intravitreal Gene Therapy for Wet AMD.

    Not in our library

  260. 260.

    Regenxbio Inc. Long-Term Follow-Up Study of RGX-314.

    Not in our library

  261. 261.

    Figueroa A.G., Boyd B.M., Christensen C.A., Javid C.G., McKay B.S., Fagan T.C., Snyder R.W. Levodopa Positively Affects Neovascular Age-Related Macular Degeneration. Am. J. Med. 2020.

    Not in our library10.1016/j.amjmed.2020.05.038

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.